Cognitive Impairments and Plasma Metabolic Characteristics in Deficit Schizophrenia: A Two-Year Follow-Up Longitudinal Study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Deficit schizophrenia (DS) is a clinically distinct subtype of schizophrenia (SZ) characterized by enduring primary negative symptoms. However, its long-term cognitive trajectory and metabolic profile remain poorly understood. This study aimed to examine progressive cognitive impairments in DS over a two-year period and to identify associated plasma metabolites and potential diagnostic biomarkers using untargeted metabolomics. Methods: A total of 126 hospitalized patients (51 DS and 75 non-DS) completed cognitive and symptom assessments using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Positive and Negative Syndrome Scale (PANSS) at baseline and two-year follow-up. Fasting plasma samples collected at baseline were analyzed using untargeted metabolomics. Repeated-measures ANOVA assessed cognitive changes in DS patients. LASSO regression, combined with cross-validation, identified potential diagnostic metabolites and their associations with cognitive impairments. Results: Over two years, patients with DS showed significant declines in cognition, mainly in visuospatial/constructional ability, attention, and delayed memory. Untargeted metabolomics identified 34 differential metabolites, primarily amino acids, fatty acids, and acylcarnitines. Pathway enrichment analysis revealed abnormalities in histidine metabolism, alanine-aspartate-glutamate metabolism, and lysine degradation. Further LASSO regression identified a 20-metabolite panel that accurately distinguished DS from non-DS patients, with an AUC of 0.929 (95% CI: 0.887-0.970). Several metabolites, including aminoadipic acid, succinylcarnitine, and gamma-glutamylthreonine, were significantly associated with cognitive impairments. Conclusions: This study is the first to reveal progressive cognitive impairments and distinct plasma metabolites in DS, identifying potential diagnostic markers and insights into its mechanisms.

Article activity feed